Our correctly folded spike, nucleocapsid or envelope COVID-19 antigens can be used to produce high-affinity vaccines.
Sengenics is a Functional Proteomics company that was originally spun out from research that was carried out at Cambridge University in the UK. The company has a patented technology called KREX™ which has world renowned customers and collaborators that include top pharma, biotech companies and Ivy League academic institutions in the USA, Europe and Asia. The company is focused on leveraging its KREX™ protein folding technology in the identification of novel biomarkers in a wide variety of human infectious and non-communicable diseases - including those where autoimmune dysfunction is involved - and their translation in to new diagnostic tests and therapies. KREX™ is also being used for a variety of applications that are critical for the Pharmaceutical industry, including: vaccine efficacy studies, predicting toxicity, protein interactions and developing companion diagnostics. The fundamental research for KREX™ was led by Professor Jonathan Blackburn as a collaboration between Oxford and Cambridge University in the early 2000s. Jonathan is the CSO of Sengenics and the inventor of KREX™.
The key application of KREX™ is the discovery of autoantibody biomarkers for two core medical use cases:
1. Drug efficacy, irAEs and CDx
Stratify patients based on autoantibody profiles detected using our KREX™ protein array technology into responders, non-responders and those exhibiting irAEs. This can guide "decision-making" strategies for improvement of drug development success rates as well as enhancing drug efficacy and safety.
2. aAB-based diagnostics and therapeutics
Discover novel autoantibody biomarkers for early diagnosis of cancers, autoimmune and neurodegenerative diseases. Some autoantibodies that identified as diagnostic biomarkers may be protective with potential in themselves as therapeutic biomolecules.
Description:
IMMUNOME™ v4 Discovery Array is a protein array which utilises the patented Sengenics KREX™ functional proteomics technology. All proteins on the IMMUNOME™ v4 Discovery Array are correctly folded and functional as they are expressed as fusion proteins with biotin carboxyl carrier protein (BCCP) which acts as a folding marker and solubility enhancer. The IMMUNOME™ v4 Discovery Array contains 1600+ full-length human proteins from biologically significant protein families including kinases, signalling molecules, cytokines, interleukins, chemokines and cancer antigens. The arrays are coated with a proprietary surface which preserves protein folding and inhibits binding of non-specific proteins.
Discovery of autoantibody biomarkers for diagnostics
Discovery of autoantibody biomarkers of risk of adverse drug reactions
Discovery of autoantibody-based therapeutic and prophylactic biologics
Determining effect of citrullination on autoantibody interactions
Functional assays for any protein or any interacting biomolecule
Specifications:
Contents and Storage:
Offered as:
Delivery lead time: 2 – 4 weeks
Description:
Specifications:
Product name: KREX™ Custom Array
Minimum Order: 25 slides
Slide Type: Streptavidin-coated glass slide
Species: Customer-specified
Contents and Storage:
Delivery lead time: 3 – 6 months
Description:
Key applications:
Specifications:
Product name: CTA Array
Minimum Order: 5 slides
Slide Type: Streptavidin-coated glass slide
Species: Human
Contents and Storage:
Delivery lead time: 4 – 6 weeks
Sengenics has not received any reviews.
Sengenics has not received any endorsements.